Development and characterization of a doxorubicin-resistant triple-negative breast cancer spheroid model for drug screening purposes
µg/µg protein) over a 96-h treatment period. A chemotherapeutic responsive MDA-MB 231 TNBC spheroid model was successfully developed and characterized. The spheroid model demonstrated sensitivity towards a clinical dose of cisplatin, whilst displaying resistance to a clinical dose of doxorubicin, based on the viability parameters.
Authors
- Beynon Abrahams (ORCID: https://orcid.org/0000-0003-3831-7719)
- Chrisna Gouws (ORCID: https://orcid.org/0000-0001-5747-8214)
- Alandi van Niekerk (ORCID: https://orcid.org/0000-0002-5797-7053)
- Mamello Sekhoacha
- Viwe Fokazi (ORCID: https://orcid.org/0000-0002-3494-0813)
Institutions
- University of the Free State (ZA)
- North-West University (ZA)
Publication Details
- Journal
- Biomedicine & Pharmacotherapy
- Published
- 2026-09-16
- DOI
- https://doi.org/10.1016/j.biopha.2026.119933
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00